Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost

被引:38
作者
Park, SH [1 ]
Yang, SH [1 ]
Lee, CG [1 ]
Youn, JW [1 ]
Chang, J [1 ]
Sung, YC [1 ]
机构
[1] Pohang Univ Sci & Technol, Div Mol & Life Sci, Natl Res Lab DNA Med, Pohang 790784, Kyungbuk, South Korea
关键词
hepatitis C virus; DNA prime-recombinant adenovirus boost; Th1CD4(+) T-cell response;
D O I
10.1016/S0264-410X(03)00499-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis C virus (HCV) is an important causative agent of liver disease, but currently there is no available prophylactic vaccine against HCV infection. Here, we investigated the HCV E2- and core-specific T-cell responses induced by DNA (D) and/or recombinant adenovirus (A) vaccines. In single (D versus A) or double immunizations (D-D versus A-A), the recombinant adenovirus vaccines induced higher levels of IFN-gamma secreting T-cell response and cytotoxic T lymphocytes (CTL) response than the DNA vaccines. However, a heterologous (D-A) regimen elicited the highest level of T helper 1 (Th1) CD4(+) T-cell responses. Furthermore, three E2-specific CTL epitopes were mapped using a peptide pool spanning the E2 protein sequence (a.a. 384-713) in BALB/c mice, and one of these (E2 405-414: SGPSQKIQLV) was shown to be immunodominant. Interestingly, no significant differences were found in the repertoire of E2-specific T-cell responses or in the immunodominance hierarchy of the three epitopes induced by D-D, D-A, A-A, and A-D, indicating that the breadth and hierarchy of T-cell responses is independent of these different vaccination regimens. In conclusion, the heterologous DNA prime-recombinant adenovirus boost regimen described offers an efficient promising strategy for the development of an effective T-cell-based HCV vaccine. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4555 / 4564
页数:10
相关论文
共 32 条
[1]  
ALTER HJ, 1989, CURRENT PERSPECTIVES, P83
[2]  
CHATSTAIN M, 2001, J PHARM SCI, V90, P474
[3]  
CHO YG, 1993, MOL CELLS, V3, P195
[4]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[5]   Gene vaccination with naked plasmid DNA: Mechanism of CTL priming [J].
Corr, M ;
Lee, DJ ;
Carson, DA ;
Tighe, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1555-1560
[6]  
DAVIS GL, 1998, NEW ENGL J MED, V339, P485
[7]   POSSIBLE MECHANISM INVOLVING T-LYMPHOCYTE RESPONSE TO NONSTRUCTURAL PROTEIN-3 IN VIRAL CLEARANCE IN ACUTE HEPATITIS-C VIRUS-INFECTION [J].
DIEPOLDER, HM ;
ZACHOVAL, R ;
HOFFMANN, RM ;
WIERENGA, EA ;
SANTANTONIO, T ;
JUNG, MC ;
EICHENLAUB, D ;
PAPE, GR .
LANCET, 1995, 346 (8981) :1006-1007
[8]   Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses [J].
Foulds, KE ;
Zenewicz, LA ;
Shedlock, DJ ;
Jiang, J ;
Troy, AE ;
Shen, H .
JOURNAL OF IMMUNOLOGY, 2002, 168 (04) :1528-1532
[9]   DNA VACCINES - PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS [J].
FYNAN, EF ;
WEBSTER, RG ;
FULLER, DH ;
HAYNES, JR ;
SANTORO, JC ;
ROBINSON, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11478-11482
[10]  
GABRIELE M, 1996, J CLIN INVEST, V98, P706